Retina

The one-day event will be held online Saturday, February 3, 2024, and is sponsored by the Bascom Palmer Eye Institute, University of Miami Health System

Investigators advised that further studies should be conducted to understand more precisely the benefits and risks

Euan Thomson, Head of the Ophthalmology Strategic Business Unit and Head of the Digital Business Unit at Carl Zeiss Meditec, discusses plans for the company's vitreoretinal surgery workflows following announcement of DORC acquisition

The European Union approval applies to aflibercept 8 mg for treatment of nAMD and DME

The study illustrates efficacy of AVT06 as compared with aflibercept (Eylea) for neovascular age-related macular degeneration

Catch up on Modern Retina's top stories, and ones you may have missed in 2023

The technology provides effective, efficient evaluations when paired with the right patients

EXN407 has the potential to be the first topical treatment for diabetic retinopathy and diabetic macular oedema

A retrospective observational study shows BCVA was maintained after 6 months for patients with neovascular AMD

In recognition of global Geographic Atrophy Week, Prevent Blindness is providing free educational resources on GA for patients, care partners and healthcare professionals

At this year’s EURETINA meeting, retina specialists highlighted important developments in diabetic macular oedema and diabetic retinopathy research

At this year's American Academy of Ophthalmology meeting in San Francisco, California, Marco A. Zarbin, MD, spoke with Ophthalmology Times about his team's post-hoc analysis of the YOSEMITE and RHINE clinical trials

At AAO 2023, Diana Do, MD, spoke with the Ophthalmology Times team about her presentation of the results for the 96-week PHOTON study of aflibercept for diabetic macular oedema

Mark Blecher, MD, spoke with the Ophthalmology Times team about his poster addressing retinal visualisation and patients who have undergone small aperture IOL implantation at this year's American Academy of Ophthalmology meeting

In the clinical trial, Oxurion’s novel PKal Inhibitor, THR-149, did not meet its primary endpoint

Developing technology may offer marked improvements in surgical precision

The endorsement follows FDA approval in the United States this summer

In this case study, a patient with recently diagnosed cancer demonstrated significant improvement for ocular symptoms of BDUMP following plasmapheresis

At the 2023 AAO meeting, Paul Runge, MD, FACS, spoke with Ophthalmology Times about his time in Ukraine treating retinopathy of prematurity (ROP) and implementing the Norlase Lion laser at this year's American Academy of Ophthalmology meeting.

Peter K. Kaiser, MD, provides an overview of innovative therapies in development for patients with dry age-related macular degeneration.

Investigators sought to estimate the costs of treating GA with pegcetacoplan and to identify possible utility measures to compare treatments for GA

Kerrie Brady, president and chief executive officer of OcuTerra Therapeutics, shares progress in their Phase 2 DR:EAM Diabetic Retinopathy study, with promising results expected in Q1 2024 for their OTT166 eye drop treatment.

The highlights from this year’s meeting, brought to you in conjunction with Modern Retina

Mutations in the EMC1 gene appear to be associated with familial exudative vitreoretinopathy (FEVR), a severe ocular condition.

Investigators emphasised a significant unmet need for home-based monitoring of visual function with patient-centric technologies

Case 1 highlights the potential for this treatment for patients with dry AMD with noted letter gains

The findings showed significant correlations between positive bacterial cultures and severe ROP, which requires diode laser and anti-VEGF treatment

ARCATUS, also known as XIPERE®, utilises a revolutionary suprachoroidal delivery platform, offering new hope to patients in China suffering from this vision-threatening condition

Robyn Guymer, MBBS, PhD, Deputy Director, Centre for Eye Research Australia, and Professor of Surgery (Ophthalmology), University of Melbourne, Australia, discussed the study findings at the 23rd annual EURETINA Congress in Amsterdam, the Netherlands

We spoke with Michael Singer, MD who provided an overview of his presentation, "MCO-010 Optogenetic Therapy to Treat Stargardt Disease: Safety and Efficacy through Week 48 in the Phase 2a STARLIGHT Clinical Trial"